Roic AI
Search
/
Search
/
Pricing
Sign inSign up

You're using the beta version. You're using the beta version of the new website.

SummaryFinancialsRatiosTranscriptsClassic View

Footer

Found an error or have an idea?
or write us an email to [email protected]

Company

  • About
  • Pricing
  • Blog

Support

  • Knowledge Base
  • FAQ

Legal

  • Privacy Policy

© 2023 Roic AI, Inc. All rights reserved.

B

Bristol-Myers Squibb Company

BMY US

BMY USBristol-Myers Squibb CompanyUSUS
FIGI: BBG000DQLV23
  1. United States Stocks
  2. •

    Healthcare
  3. •

    Drug Manufacturers—General
Business
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Company News

  • MarketWatch.com

    4 days ago

    As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment 

  • Dow Jones Newswires

    6 days ago

    Merck Gets FDA Priority Review of Sotatercept in Pulmonary Arterial Hypertension >MRK

  • The Wall Street Journal

    7 days ago

    The Big Pharma Trade: Ozempic Is In, Covid-19 Is Out

  • The Wall Street Journal

    11 days ago

    Health Care Roundup: Market Talk

  • The Wall Street Journal

    13 days ago

    This Cancer Therapy is Lifesaving, but There Isn’t Enough of It

  • The Wall Street Journal

    21 days ago

    Eliquis for $55 a Month? That Is News to Us

  • Barron's

    23 days ago

    Stocks Are Flat Ahead of Data

  • Barron's

    23 days ago

    Apple, Moderna, Inflation, and More to Watch

  • The Wall Street Journal

    25 days ago

    Big Pharma’s Battle With the Biden Administration Could Have Legs

  • The Wall Street Journal

    a month ago

    Biden FTC’s Antitrust Bark Proves Worse Than Its Bite

  • Barron's

    a month ago

    Medicare's Plan to Negotiate Drug Discounts Won't Hit Pharma Hard, Analysts say

  • The Wall Street Journal

    a month ago

    Drug Price Controls Mean Slower Cures

  • Dow Jones Newswires

    a month ago

    Healthcare Shares Rise but Lag Broader Market -- Healthcare Roundup

  • Barron's

    a month ago

    First 10 Drugs Picked for Medicare Price Negotiations

  • MarketWatch.com

    a month ago

    Eliquis, Jardiance among first 10 drugs selected for Medicare price negotiations

  • The Wall Street Journal

    a month ago

    The High Cost of Price Controls on Eliquis and Other Drugs

  • Barron's

    a month ago

    Biden Administration to Reveal 10 Drugs for Which Medicare Will Pay Less

  • Dow Jones Newswires

    a month ago

    BMY Gets European Approval for Opdivo as Treatment for Some Melanoma Patients

  • Barron's

    2 months ago

    In a Tough Year for Pharma, These 6 Stocks Are Shining

  • The Wall Street Journal

    2 months ago

    Could Scientist Find Drug to Treat His Own Disease?

57.22

USD
-0.63
(-1.09%)
3.75EPS Dil.
15.15P/E
119.53BMarket Cap
3.89%Div. Yield
Bristol-Myers Squibb Company
BMY
(United States Composite)

Recent

price

57.22

P/E

ratio

15.15

div

yld

3.89%

ROIC.AI

Capital Structure
USD

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
4,400
2,923
3,188
LT Borrowings
35,056
35,078
34,656
LT Finance Leases
1,261
1,370
1,342
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,075
2,100
2,089
Market Capitalization
149,296
145,551
133,592
Working Capital
USD

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
27,273
27,086
28,074
Cash, Cash Equivalents & STI
9,253
9,269
8,730
Accounts Receivable, Net
8,151
7,854
8,125
Inventories
2,339
2,605
2,364
Total Current Liabilities
21,890
19,085
20,150
Payables & Accruals
5,499
5,919
6,090
ST Debt
4,400
2,923
3,188
Deferred Revenue
- -
- -
- -
Growth Rates
USD

•

in mil. unless spec.
(avg. rate of change)
10 years
5 years
1 year
Sales/Revenue/Turnover
11.42%
19.14%
-0.49%
Net Income, GAAP
-10.10%
-37.61%
-9.54%
Free Cash Flow
23.25%
28.01%
-21.57%
Total Cash Common Dividend
8.15%
13.86%
5.41%
Total Equity
23.21%
47.99%
-13.58%
Quarterly Revenue
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
11,073
11,703
11,624
11,985
46,385
2022
11,648
11,887
11,218
11,406
46,159
2023
11,337
11,226
- -
- -
- -
Quarterly Earnings Per Share
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
0.90
0.47
0.70
1.10
3.15
2022
0.60
0.67
0.75
0.96
2.97
2023
1.08
0.99
- -
- -
- -
Quarterly Dividends Per Share
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
0.50
0.49
0.49
0.51
1.98
2022
0.55
0.54
0.54
0.54
2.18
2023
0.57
0.57
- -
- -
- -
Legends:
Stock price
0.19
Beta (1.0 Market)
% total return 10/04
Stock
S&P500
YTD
-18.76
- -
3Y
6.49
- -
5Y
- -
- -
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
USD
9.82
10.42
9.53
11.37
12.50
10.55
9.97
9.58
9.93
11.63
12.63
13.82
15.33
18.83
20.88
21.67
21.43
Revenue per ShareRevenue per Share
1.10
2.65
5.38
1.81
2.18
1.17
1.56
1.21
0.97
2.67
0.61
3.03
2.02
-3.99
3.15
2.97
3.78
Basic EPS, GAAPBasic EPS, GAAP
1.17
1.40
1.69
2.37
2.63
3.83
1.83
1.58
0.61
0.98
2.57
3.06
4.24
5.89
6.86
5.61
5.08
Free Cash Flow per Basic ShareFree Cash Flow per Basic Share
1.12
1.24
1.26
1.29
1.33
1.37
1.40
1.45
1.49
1.52
1.57
1.60
1.57
1.80
1.98
2.18
2.23
Dividend per ShareDividend per Share
10.12
11.49
18.13
18.75
19.76
20.22
20.22
19.82
19.17
20.27
19.31
21.11
15.60
9.71
11.20
12.43
13.28
Book Value per ShareBook Value per Share
2.14
3.16
3.92
4.14
4.25
-1.70
3.55
3.75
3.69
4.86
2.32
4.00
-15.60
-16.17
-12.67
-12.72
-10.01
Tangible Book Value per ShareTangible Book Value per Share
1,970
1,977
1,974
1,713
1,700
1,670
1,644
1,657
1,667
1,671
1,645
1,633
1,705
2,258
2,221
2,130
2,109
Basic Weighted Avg SharesBasic Weighted Avg Shares
19,348
20,597
18,808
19,484
21,244
17,621
16,385
15,879
16,560
19,427
20,776
22,561
26,145
42,518
46,385
46,159
45,187
Sales/Revenue/TurnoverSales/Revenue/Turnover
18.23
27.78
25.56
33.36
33.12
22.31
17.89
10.79
10.45
23.36
16.61
22.69
22.62
5.12
18.40
19.72
17.98
Operating Margin (%)Operating Margin (%)
892
816
707
744
801
681
763
467
376
382
789
637
1,135
9,688
10,023
9,595
9,444
Depreciation ExpenseDepreciation Expense
2,165
5,247
10,612
3,102
3,709
1,960
2,563
2,004
1,624
4,457
1,007
4,952
3,439
-9,015
6,994
6,327
7,963
Net Income, GAAPNet Income, GAAP
22.72
24.13
21.10
25.66
24.65
- -
10.76
14.78
22.01
23.80
81.00
17.15
30.45
- -
13.39
17.74
8.28
Effective Tax Rate (%)Effective Tax Rate (%)
11.19
25.47
56.42
15.92
17.46
11.12
15.64
12.62
9.81
22.94
4.85
21.95
13.15
-21.20
15.08
13.71
17.62
Profit Margin (%)Profit Margin (%)
1,704
8,053
7,645
6,534
7,538
1,242
6,476
6,147
2,398
4,863
5,291
7,181
11,050
11,112
11,394
5,383
7,924
Working CapitalWorking Capital
4,381
6,585
6,130
5,328
5,376
6,568
7,981
7,242
6,550
5,716
6,975
5,646
44,059
49,169
40,479
36,317
35,998
LT DebtLT Debt
10,562
12,241
14,785
15,638
15,867
13,638
15,236
14,983
14,424
16,347
11,847
14,127
51,698
37,882
36,006
31,118
32,030
Total EquityTotal Equity
15.92
24.01
18.66
22.75
24.93
- -
11.69
6.26
6.06
15.51
3.06
20.49
6.75
- -
8.64
9.75
10.05
Return on Invested Capital (%)Return on Invested Capital (%)
5.22
14.41
28.48
4.83
5.97
- -
6.65
5.23
4.29
11.44
2.69
12.51
6.24
- -
11.36
10.74
13.40
Return on Capital (%)Return on Capital (%)
10.81
24.55
39.49
9.87
11.39
5.92
7.75
6.08
5.03
13.60
3.09
15.08
9.96
-32.00
30.62
25.36
30.48
Return on Common Equity (%)Return on Common Equity (%)